Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Keyword
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 2 Component(s) Recorded On: 08/09/2022

    As the home infusion industry has changed due to the COVID pandemic, staffing challenges are increasing, and growth goals are remaining aggressive.

    As the home infusion industry has changed due to the COVID pandemic, staffing challenges are increasing, and growth goals are remaining aggressive. During this webinar, we will discuss strategies for optimizing your team to support staff and revenue retention and overall growth, and how the right workflow optimization strategy can have a positive impact on your top and bottom lines.

    LEARNING OBJECTIVES:

    1. Gaining an understanding of the connection between staffing, revenue retention and growth.
    2. Explore doing more with less and retaining talent through prescriptive and collaborative workflows.
    3. Dive into the impacts patient and family engagement can have on your organization, satisfaction scores and growth goals.

    Terri Embry

    RN, BSBA

    Citus Healthcare

    A registered nurse with a bachelor’s degree in business and marketing, Terri’s career has spanned almost three decades in regional and national home, specialty and long-term care infusion operations, sales, and informatics leadership. Her experience with cutting-edge workflow optimization has allowed her to understand the challenges both customers and their patients face. With CitusHealth, she leads the adoption and retention team helping to bring the voice of customers to the product development roadmap.

    Terri has been in leadership, sales, and nursing roles for companies such as BioScrip, Omnicare, and Olsten-Kimberly Quality Care.

  • Contains 4 Component(s), Includes Credits

    Multi-drug resistant tuberculosis (MDR-TB) has become a leading world health crisis. MDR-TB is defined as resistance to the potent cornerstone TB drugs, isoniazid and rifampin. Approximately, 3% of newly infected cases and 20% of pre-existing TB cases are diagnosed with MDR-TB.

    Multi-drug resistant tuberculosis (MDR-TB) has become a leading world health crisis. MDR-TB is defined as resistance to the potent cornerstone TB drugs, isoniazid and rifampin. Approximately, 3% of newly infected cases and 20% of pre-existing TB cases are diagnosed with MDR-TB. 

    In recent years, aminoglycosides have become a part of the backbone of MDR-TB treatments. The most common aminoglycosides used for pulmonary TB are amikacin and streptomycin. Despite the lack of data on specific amikacin dosing and duration of treatment, it is still widely used as an add-on therapy in non-responsive MDR-TB patients. This article will review amikacin dosing and its use based on current guidelines; explore amikacin pharmacokentics and pharmacodynamics and dosing; explore the relationship between aminoglycosides and ototoxicity; and distinguish between monitoring methods in the home infusion setting.  

    LEARNING OBJECTIVES:

    1. Provide an overview of tuberculosis, multi-drug resistant tuberculosis (MDR-TB), and history of amikacin use.
    2. Understand aminoglycoside dosing and its use based on current guidelines.
    3. Comprehend amikacin pharmacokinetics and pharmacodynamics.
    4. Appreciate the relationship between aminoglocosides and ototoxicity.
    5. Distinguish between monitoring methods in the home infusion setting.

    Vy Dang

    PharmD

    Optum Infusion Services

    Vy Dang, Pharm.D, HDDP is an Infusion Clinical Pharmacist at Optum Infusion Services in Wallingfor, Connecticut. She earned a Bachelor’s degree in Health Sciences at University of California, Irvine and a Doctor of Pharmacy degree at Roseman University of Health Sciences College of Pharmacy. Dang was a pharmacy practice resident in Las Vegas. She has practiced in infectious disease, genetics, oncology, and emergency medicine. Her current practice focuses on parenteral nutrition, acute care, inotropes, IV anti-infective agents, and pain management. She also provides clinical care for high-cost IV drugs including immunoglobulins (IGs), enzyme replacement therapies (eg. Fabrazyme), Radicava, Solaris, Entyvio, biologics, and alpha-1 proteinase inhibitors (eg. Glassia, Zemaira). Dang is currently licensed in Arizona, Connecticut, Massachusetts, Nevada and Ohio.

    No Disclosures to Report

  • Contains 2 Component(s) Recorded On: 06/15/2022

    A strong sales strategy creates the foundation for a cohesive and successful sales organization and helps to scale and grow your business. So, how do you create the best and most effective sales strategy?

    A strong sales strategy creates the foundation for a cohesive and successful sales organization and helps to scale and grow your business.

    So, how do you create the best and most effective sales strategy?

    Join John King, Executive Vice President of Sales & Operations for Vitalcare Infusion Services, for a webinar where he will share how his sales team utilizes market insights to form a strategic sales process. John will also discuss how market insights have allowed his team to enhance referral source targeting, assess new market opportunities, and grow their business.

    Learning Objectives:

    1. Identify and target the highest potential referrals.
    2. Analyze market trends and forecast sales.
    3. Defferentiate from the competition.
    4. Empower your sales and marketing team.

    John King

    Executive Vice President of Sales and Ops

    Vital Care Infusion Services

    John King is currently serving as the Executive Vice President of Sales & Ops for Vital Care Infusion Services. He recently served as the Senior Vice President of Sales at Kroger Specialty Pharmacy. Mr. King is a seasoned Senior Sales Executive with a demonstrated knowledge of strategic sales models, building strong sales teams and innovative marketing strategies, therapeutic market development, and exceptional customer service.

    No Disclosures to Report

    Jason Dillon

    Sales Manager

    Playmaker/Trella Health

    Jason Dillon, Regional Sales Manager with Trella Health, is a seasoned sales professional with experience in both healthcare and cutting-edge software solutions. His understanding of how HME and Infusion providers can drive business growth using technology is matched only by his desire to solve the day-to-day business challenges of post-acute care providers across the country.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits Recorded On: 06/02/2022

    Drug Diversion can occur anywhere there is access to controlled substances and high-value medications. The home infusion setting brings its own unique challenges and areas of risk. It also brings opportunity for real impact in the patient’s home surrounding substance abuse.

    Drug Diversion can occur anywhere there is access to controlled substances and high-value medications. The home infusion setting brings its own unique challenges and areas of risk. It also brings opportunity for real impact in the patient’s home surrounding substance abuse. Join us as we discuss the main points of failure and learn how we can close those gaps to make things safer for our patients and healthcare professionals. 

    Learning Objectives:

    1. Define drug diversion and its prevalence among healthcare professionals.
    2. Recognize the need to evaluate chain of custody procedures for controlled substances.
    3. Recognize unusual events that may warrant diversion consideration.

    Theresa Vidals

    Pharmacist

    Rxpert Solutions

    Theresa “Terri” has been a pharmacist for over 30 years with 15 years of experience inmedication safety and drug diversion monitoring. Her background includes work in variousclinical roles, as well as leadership roles such as Pharmacy Operations Manager, MedicationSafety Officer and Pharmacy Director. She has overseen and started diversion monitoringprograms at healthcare facilities. Terri is a subject matter expert in drug diversion preventionand monitoring. In addition to her years of experience in hospital pharmacy and involvement indrug diversion prevention and monitoring, she possesses the ability to see the big picture. Sheknows what to look for and how to look for it. While she is compassionate toward healthcareprofessionals that have a substance abuse problem, she also understands the safety risks andis not afraid to ask the hard questions during investigation interviews. She is also the host ofDrug Diversion Insights, a podcast for those in the healthcare industry looking for ways toreduce substance abuse and drug diversion. She founded Rxpert Solutions so that all facilitieswould have access to her expertise as an alternative to, or to act as a bridge while waiting for,personnel on site to develop the expertise.

    No Disclosures to Report

  • Contains 2 Component(s) Recorded On: 05/24/2022

    Join NHIA staff members for a webinar as we discuss the latest happening in the home and alternate site infusion industry and the best ways to get involved.

    Join NHIA staff members for a webinar as we discuss the latest happening in the home and alternate site infusion industry and the best ways to get involved.

    We'll also discuss:

    • Efforts to modernize the home infusion coding system
    • Regulatory and reimbursement updates
    • NHIA committee and how to get involved
    • Research opportunities & how to submit to infusion Journal
    • Resources to help you perform and write your own research

    2022 Talk Infusion Webinar series is generously supported by McKesson.

    Shea McCarthy

    Director of Legislative Affairs

    NHIA

    As a respected lobbyist and health policy analyst representing some of Washington’s most influential stakeholders, Shea McCarthy serves as NHIA's Director of Legislative Affairs as well as a full time consultant.  As a Senior Vice President at the firm Thorn Run Partners, Mr. McCarthy advises clients on the intricacies of health care policy, develops sophisticated government relations strategies, and has successfully influenced federal laws. By offering a deeply coordinated approach to advocacy — combining facets of technology, grassroots engagement, PR, and traditional lobbying — Mr. McCarthy and his team of experts actively position stakeholders for success. 

    His experience has also been leveraged in the political arena, where he's worked on the Digital Events team for Mitt Romney’s Presidential campaign. Before to joining Thorn Run, Mr. McCarthy worked on in the office of Sen. Cory Gardner (R-CO). He is widely regarded as a thought leader in the health policy field, and his analysis has been featured in leading national and inside-the-Beltway publications such as Business Insider, STAT News, Inside Health Policy, Modern Healthcare, Morning Consult, and RealClearHealth.

    He received his Bachelor's degree from the University of Notre Dame.

    No Disclosures to Report

    Bill Noyes

    Sr VP of Reimbursement Policy

    NHIA

    Bill Noyes is the Senior Vice President of Reimbursement Policy at the National Home Infusion Association (NHIA). He joined NHIA in 2012 as Vice President of Health Information Policy, focusing on reimbursement and regulatory issues affecting providers' ability to do business and collect payment for their services. Noyes sits on four Medicare Contractor Advisory Councils and is the liaison to NHIA's reimbursement-focused committees. He also works closely with the NHIA government relations team to gain more meaningful Medicare coverage for home infusion. He served as Interim CEO of the associaiton from July 2018 to November 2018. Prior to joining NHIA, Noyes spent 20 years as Vice President of Operations for a multi-state home infusion provider where he was responsible for purchasing, distribution, facilities, revenue cycle management, and pharmacy operations.

    No Disclosures to Report

    Ryan Garst, PharmD, MBA, IgCP, BCSCP

    Sr Director Clinical Services

    NHIA

    Ryan Garst, Pharm D, MBA, BCSCP is the Senior Director of Clinical Services at the National Home Infusion Association. Garst has almost 15 years of experience in home infusion and nearly twenty years of experience in pharmacy clinical and operational leadership and management, information technology, sales, and clinical practice experience. At NHIA, Garst is responsible for clinical education and services, Infusion Magazine Clinical Editor, and oversees a variety of programs administered by the National Home Infusion Foundation including the industry resident program, the National Benchmarking Program, and clinical trials and research. Prior to joining NHIA, Garst served on a variety of committees for the association and participated in numerous annual conferences. Garst holds a Doctor of Pharmacy degree from Ohio Northern University and a Master of Business Administration from Kent State University and is Board Certified in Sterile Compounded Preparations via BPS.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits

    Cleaning. The term sounds simple enough. Yet, when applied to sterile compounding areas, the term becomes complex. It not only covers the mechanical act of cleaning but the selection and application of different, essential agents.

    Cleaning. The term sounds simple enough. Yet, when applied to sterile compounding areas, the term becomes complex. It not only covers the mechanical act of cleaning but the selection and application of different, essential agents. Additionally, procedures for the act of cleaning and a schedule determining when and which items and areas are cleaned, are essential to compounding operations. The 2021 version of USP General Chapter <797> improved upon the language surrounding the agents used in sterile compounding areas, but there is still confusion around what the agents do and what defines an appropriate agent. This article explores the agents used to meet the cleaning requirements of USP General Chapter <797> and does not address deactivation and decontamination, as required by USP General Chapter <800>.

    Learning Objectives:

    1. Distinguish between cleaning (removing soil load) and disinfecting (killing microorganisms).
    2. Be able to determine which type of agent to use for daily, optional weekly, and monthly cleaning in your own sterile compounding environment.
    3. Understand the advantages and disadvantages of several common agents used in sterile compounding areas.

    Abby Roth, BS, CMQ/OE

    Sr Director Business Operations

    Critical Point LLC

    Abby Roth, BS, CMQ/OE is the Senior Director of Business Operations at CriticalPoint LLC, a health care consulting firm. She has more than 15 years of experience in supporting the testing and consulting needs of the pharmaceutical, medical device, and compounding industries. Her background in pharmaceutical microbiology includes extensive knowledge of environmental monitoring, including program development, sampling technique sample analysis, and data trending, as well as product testing. Roth also has experience in consulting on microbiological contamination sources and remediation. She served on the USP Expert Panel on Sterile Compounding and is an active member of the Controlled Environment Testing Association (CETA). Roth earned a bachelor of science in Biology with a minor in Chemistry from York College of Pennsylvania.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits Recorded On: 05/11/2022

    With downward pressure on drug reimbursement, home infusion providers need to consider their overall “cost of service” for each therapy in their service lines. Cost of service should be a consideration when evaluating new home infusion drugs and payer contracts.

    With downward pressure on drug reimbursement, home infusion providers need to consider their overall “cost of service” for each therapy in their service lines. Cost of service should be a consideration when evaluating new home infusion drugs and payer contracts. This webinar will guide providers through calculating these costs and negotiating appropriately. 

    Learning Objectives:

    1. Evaluate your home infusion pharmacy's profitability by therapy/drug and be better prepared when entering into uncharted territory.
    2. Define the key components in calculating costs and determining profitability by therapy to make better, more informed decisions in the future.
    3. Learn the top tips for entering into new payer contracts.

    Jeanne Lugli

    Sr Director of Operations

    Brightree

    Jeanne Lugli has more than 38 years’ experience in home infusion reimbursement. She began her infusion career at Home Health Care of America (which later became Caremark) as part of the intake team and eventually was promoted to Reimbursement Manager.  Jeanne credits her hands-on experiences at Caremark for building the foundation of her overall infusion knowledge.  She went on to work at Home Intensive Care (HIC) as the Regional Reimbursement Manager overseeing the billing and collections for 13 regional locations.  After HIC was acquired by NMC Homecare and her office was eliminated, she went to work for Healthcare Automation (HAI), who was subsequently acquired by WellSky.  HAI was an infusion software company.  Jeanne spent the first two years at HAI offering expert consulting in home infusion reimbursement to more than 100 infusion pharmacies throughout the country and Puerto Rico.  In 1995, she started the home infusion reimbursement outsourcing division which over the next 25 years grew from 2 employees and $200k in annual sales to 70+ employees and $8m+ in annual sales.  Since 2020, she is a Sr. Director of Operations for Pharmacy & Infusion at Brightree, a division of ResMed.  At Brightree Jeanne is overseeing Brightree’s growing home infusion RCM services.  Lastly, Jeanne has been on the National Home Infusion Association Payer Advocacy and Relations Committee since 2007.

    No Disclosures to Report

    Jennifer Keiser

    Pharmacy Product Manager

    Brightree LLC

    Jennifer Keiser is the Pharmacy Product Manager, Brightree LLC. Jen is responsible for product strategy, feature prioritization and product roadmap for the pharmacy offerings within Brightree’s cloud-based post-acute care solutions. She has over 25 years of experience managing software development, support and implementations but her true love is designing exceptional pharmacy software. She was previously General Manager of the Alternate Care Solutions division of Mediware and a Senior Manager of Business Analysis at CVS Health. Jen earned a BS in Computer Science from the University of Illinois and a ALM in Information Technology from Harvard.

    No disclosures to Report

  • Contains 3 Component(s) Recorded On: 05/02/2022

    NHIA is seeking member review and comment on a proposal to request modifications to the home infusion Healthcare Common Procedure Coding System (HCPCS) codes (S-codes).

    NHIA is seeking member review and comment on a proposal to request modifications to the home infusion Healthcare Common Procedure Coding System (HCPCS) codes (S-codes). The existing S-codes were developed by a group of NHIA members 20 years ago and have not been substantially changed since introduced in 2002. The code set was robust with specific codes reflective of the infused therapies delivered in the home at the time and accomplished the goal of standardizing billing procedures across various payers, reducing the administrative burden on providers, and improving the ability to negotiate contract terms. 

    Bill Noyes

    Sr VP of Reimbursement Policy

    NHIA

    Bill Noyes is the Senior Vice President of Reimbursement Policy at the National Home Infusion Association (NHIA). He joined NHIA in 2012 as Vice President of Health Information Policy, focusing on reimbursement and regulatory issues affecting providers' ability to do business and collect payment for their services. Noyes sits on four Medicare Contractor Advisory Councils and is the liaison to NHIA's reimbursement-focused committees. He also works closely with the NHIA government relations team to gain more meaningful Medicare coverage for home infusion. He served as Interim CEO of the associaiton from July 2018 to November 2018. Prior to joining NHIA, Noyes spent 20 years as Vice President of Operations for a multi-state home infusion provider where he was responsible for purchasing, distribution, facilities, revenue cycle management, and pharmacy operations.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits Recorded On: 03/31/2022

    Infusion providers are continuing to search for new ways to do more with less as the effects of Covid-19 continue to strain resources. Leveraging technology is no brainer to drive efficiency and productivity within your organization, but all tech is not created equal. As the tech landscape expands rapidly, landing on the right solution and vendor that can deliver can feel like a roll of the dice.

    Infusion providers are continuing to search for new ways to do more with less as the effects of Covid-19 continue to strain resources. Leveraging technology is no brainer to drive efficiency and productivity within your organization, but all tech is not created equal. As the tech landscape expands rapidly, landing on the right solution and vendor that can deliver can feel like a roll of the dice.

    PlayMaker Health’s data solutions and sales intelligence, utilized by more than 2,300+ home health, hospice, HME and infusion organizations nationwide, combines current claims data sets, clinical operational metrics, and real-time sales insights. Delivered through our mobile CRM, agencies have the answers they need to sell faster, scale smarter, and compete.

    PlayMaker Health is now part of Trella Health! The industry’s most comprehensive market intelligence, CRM, and EMR integrations solutions – now together in one platform.

    Learning Objectives:

    1. Why you need to look beyond the price when evaluating technology.
    2. How to create buy-in across the team before the demos are scheduled.
    3. How to avoid common mistakes that can slow down the evaluation process.
    4. Understanding common implementation pitfalls that can kill momentum.

    Jason Dillon

    Sales Manager

    Playmaker/Trella Health

    Jason Dillon, Regional Sales Manager with Trella Health, is a seasoned sales professional with experience in both healthcare and cutting-edge software solutions. His understanding of how HME and Infusion providers can drive business growth using technology is matched only by his desire to solve the day-to-day business challenges of post-acute care providers across the country.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits

    This program will provide education related to the 2021 FDA-approved drugs that are pertinent to the home and alternate site infusion industry because they are administered by intravenous infusion or injection.

    This program will provide education related to the 2021 FDA-approved drugs that are pertinent to the home and alternate site infusion industry because they are administered by intravenous infusion or injection. Each drug (17 total) will receive a brief review discussing its indication as well as incidence and clinical course of disease(s) treated. Reviews will also cover the drug’s mechanism of action, the clinical trials leading to FDA approval, home infusion pharmacy considerations for storage, compounding and administration of the drug; nursing and patient education considerations, and pricing information.

    Learning Objectives:

    1. Review the new FDA approved drugs from 2021 that relate to the home and specialty infusion industry.
    2. Understand the indications for the new FDA drugs approved in 2021.
    3. Review the clinical characteristics of the new FDA drugs approved in 2021.
    4. Discuss clinical, compounding, administration, and nursing considerations for the new FDA approved drugs in 2021.

    Ryan Garst, PharmD, MBA, IgCP, BCSCP

    Sr Director Clinical Services

    NHIA

    Ryan Garst, Pharm D, MBA, BCSCP is the Senior Director of Clinical Services at the National Home Infusion Association. Garst has almost 15 years of experience in home infusion and nearly twenty years of experience in pharmacy clinical and operational leadership and management, information technology, sales, and clinical practice experience. At NHIA, Garst is responsible for clinical education and services, Infusion Magazine Clinical Editor, and oversees a variety of programs administered by the National Home Infusion Foundation including the industry resident program, the National Benchmarking Program, and clinical trials and research. Prior to joining NHIA, Garst served on a variety of committees for the association and participated in numerous annual conferences. Garst holds a Doctor of Pharmacy degree from Ohio Northern University and a Master of Business Administration from Kent State University and is Board Certified in Sterile Compounded Preparations via BPS.

    No Disclosures to Report